BRPI1003661A2 - associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose - Google Patents

associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose Download PDF

Info

Publication number
BRPI1003661A2
BRPI1003661A2 BRPI1003661-0A BRPI1003661A BRPI1003661A2 BR PI1003661 A2 BRPI1003661 A2 BR PI1003661A2 BR PI1003661 A BRPI1003661 A BR PI1003661A BR PI1003661 A2 BRPI1003661 A2 BR PI1003661A2
Authority
BR
Brazil
Prior art keywords
endometriosis
fibroid
treatment
prevention
resveratrol
Prior art date
Application number
BRPI1003661-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Hugo Da Silva Maia Jr
Original Assignee
Libbs Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Libbs Farmaceutica Ltda filed Critical Libbs Farmaceutica Ltda
Priority to BRPI1003661-0A priority Critical patent/BRPI1003661A2/pt
Priority to EP14197294.3A priority patent/EP2965762A1/en
Priority to EP20110824381 priority patent/EP2617425A4/en
Priority to PCT/BR2011/000366 priority patent/WO2012034204A1/pt
Priority to ARP110103364 priority patent/AR082998A1/es
Priority to BR112013003668-0A priority patent/BR112013003668B1/pt
Priority to US13/824,010 priority patent/US20130267485A1/en
Priority to CA2811456A priority patent/CA2811456C/en
Publication of BRPI1003661A2 publication Critical patent/BRPI1003661A2/pt
Priority to US14/522,934 priority patent/US20150111861A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
BRPI1003661-0A 2010-09-15 2010-09-15 associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose BRPI1003661A2 (pt)

Priority Applications (9)

Application Number Priority Date Filing Date Title
BRPI1003661-0A BRPI1003661A2 (pt) 2010-09-15 2010-09-15 associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
EP14197294.3A EP2965762A1 (en) 2010-09-15 2011-09-15 Pharmaceutical combination of resveratrol and progestin to treat and/or prevent myoma and/or endometriosis
EP20110824381 EP2617425A4 (en) 2010-09-15 2011-09-15 PHARMACEUTICAL ASSOCIATION FOR TREATING AND / OR PREVENTING MYOMA AND / OR ENDOMETRIOSIS, USE OF RESVERATROL AND PROGESTOGEN, PHARMACEUTICAL COMPOSITION FOR TREATING AND / OR PREVENTING MYOMA AND / OR ENDOMETRIOSIS, KIT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF MYOMA AND / OR ENDOMETRIOSIS
PCT/BR2011/000366 WO2012034204A1 (pt) 2010-09-15 2011-09-15 Associação farmacêutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composição farmacêutica para tratamento e/ou prevenção de mioma e/ou endometriose, medicamento para tratamento e/ou prevenção de mioma e/ou endometriose, kit e método para tratamento e/ou prevenção de mioma e/ou endometriose
ARP110103364 AR082998A1 (es) 2010-09-15 2011-09-15 Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
BR112013003668-0A BR112013003668B1 (pt) 2010-09-15 2011-09-15 Associação farmacêutica para tratar e/ou prevenir mioma e/ou endometriose e seu uso
US13/824,010 US20130267485A1 (en) 2010-09-15 2011-09-15 Pharmaceutical Combination of Resveratrol and Progestin to Treat and/or Prevent Myoma and/or Endometriosis
CA2811456A CA2811456C (en) 2010-09-15 2011-09-15 Pharmaceutical combination of resveratrol and progestin to treat and/or prevent myoma and/or endometriosis
US14/522,934 US20150111861A1 (en) 2010-09-15 2014-10-24 Pharmaceutical Combination of Resveratrol and Progestin to Treat and/or Prevent Myoma and/or Endometriosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI1003661-0A BRPI1003661A2 (pt) 2010-09-15 2010-09-15 associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose

Publications (1)

Publication Number Publication Date
BRPI1003661A2 true BRPI1003661A2 (pt) 2013-01-08

Family

ID=45830891

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI1003661-0A BRPI1003661A2 (pt) 2010-09-15 2010-09-15 associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
BR112013003668-0A BR112013003668B1 (pt) 2010-09-15 2011-09-15 Associação farmacêutica para tratar e/ou prevenir mioma e/ou endometriose e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013003668-0A BR112013003668B1 (pt) 2010-09-15 2011-09-15 Associação farmacêutica para tratar e/ou prevenir mioma e/ou endometriose e seu uso

Country Status (6)

Country Link
US (2) US20130267485A1 (pt-PT)
EP (2) EP2617425A4 (pt-PT)
AR (1) AR082998A1 (pt-PT)
BR (2) BRPI1003661A2 (pt-PT)
CA (1) CA2811456C (pt-PT)
WO (1) WO2012034204A1 (pt-PT)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
FR3110401B1 (fr) * 2020-05-19 2023-07-07 Gynov Compositions et combinaisons destinées aux sujets souffrant d’endométriose
US20240122885A1 (en) * 2021-02-12 2024-04-18 The Regents Of The University Of California Endometriosis-Related Methods and Compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
US6498154B1 (en) * 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
WO2003017973A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
PT1443966E (pt) * 2001-11-15 2007-06-21 Pantarhei Bioscience Bv Método para a prevenção ou tratamento das doenças ginecológicas benignas
US20040146539A1 (en) * 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
EP1462106A1 (en) * 2003-03-28 2004-09-29 Pantarhei Bioscience B.V. Pharmaceutical compositions and kits comprising 17-beta-estradiol and a progesteron for the treatment of gynecological disorders
WO2004098517A2 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050113350A1 (en) * 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
US20060079491A1 (en) * 2004-10-08 2006-04-13 Andreas Sachse Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol
PE20070182A1 (es) * 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
WO2007084857A2 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose

Also Published As

Publication number Publication date
US20130267485A1 (en) 2013-10-10
WO2012034204A1 (pt) 2012-03-22
EP2617425A4 (en) 2014-02-19
EP2617425A1 (en) 2013-07-24
BR112013003668A2 (pt) 2021-04-27
US20150111861A1 (en) 2015-04-23
CA2811456C (en) 2015-06-16
AR082998A1 (es) 2013-01-23
EP2965762A1 (en) 2016-01-13
BR112013003668B1 (pt) 2022-03-03
CA2811456A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
BRPI1003661A2 (pt) associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
ES2625950T3 (es) Composición farmacéutica para la anticoncepción de emergencia
US20100021529A1 (en) Step-down estrogen regimen for women receiving estrogen therapy
ES2281551T3 (es) Metodo de prevencion o tratamiento de enfermedades ginecologicas benignas.
TW200831107A (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
PT2741824T (pt) Utilização de estetrol como contracetivo de emergência
TW200307553A (en) Treatment of post-menopausal complaints in breast cancer patients
Goldberg et al. Mifepristone (RU 486): current knowledge and future prospects
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
JP2012077020A (ja) ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
UA73956C2 (en) Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
Maia et al. Short Term Effects of the Vaginal Administration of Gestrinone and Miodesi on Endometriosis Pain
Singh et al. Medical Management of endometriosis
CA3234836A1 (en) Contraceptive regimen including reduced level of estrogen
US8193252B1 (en) Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
TW200942242A (en) New drospirenone/17β-estradiol regimen, pharmaceutical combination product and kit for performing this regimen

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2192 DE 08/01/2013, QUANTO AO ITEM (51).

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]